Liquid-Biopsy Glycan Score Biomarker Accurately Indicates and Stratifies Primary and Metastatic Prostate Cancers

Ana Díaz-Fernández, Mads Ryø Jochumsen, Nana Louise Christensen, Karina Dalsgaard Sørensen, Kirsten Bouchelouche, Michael Borre, Mikkel Holm Vendelbo, Elena E. Ferapontova*

*Corresponding author for this work

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Abstract

Prostate cancer (PCa) is the most commonly diagnosed cancer in males. Early PCa usually shows no clinical symptoms and its primary diagnosis is currently guided by liquid-biopsy testing of serum prostate-specific antigen (PSA). This testing suffers from high false-positive and false-negative rates. Identifying new biomarkers for precise liquid-biopsy detection of PCa is, thus, an acute clinical request. Here, by using an advanced dual-functional aptamer assay, we quantified the extent of glycosylation of PSA circulating in cancer patients’ serum, linked it to cancer-related breakage of PSA complexes with serum-circulating proteins, and proved its facility for stratification of primary and metastatic PCa. PSA’s “Glycan Score” 100% accurately informed about PCa status in a 30-patient cohort, while serum PSA’s concentration correctly classified only 53% of PCa patients and did not inform about their PCa status. The Glycan Score liquid-biopsy test thus has a huge potential for accurate diagnosis and staging of PCa, enabling mass-screening program progress and advanced PCa treatment monitoring.

Original languageEnglish
JournalAnalytical Chemistry
Volume96
Issue47
Pages (from-to)18815-18823
Number of pages9
ISSN0003-2700
DOIs
Publication statusPublished - 26 Nov 2024

Fingerprint

Dive into the research topics of 'Liquid-Biopsy Glycan Score Biomarker Accurately Indicates and Stratifies Primary and Metastatic Prostate Cancers'. Together they form a unique fingerprint.

Cite this